Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 6, 2009, Pages 354-359

  Undas, Anetta ^a   Topór Ma̧dry, Roman ^a   Tracz, Wiesława ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cholesterol; Fibrin clot; Fibrinolysis; Statins

Indexed keywords

C REACTIVE PROTEIN; FIBRIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; FEMALE; GROUPS BY AGE; HUMAN; MALE;

EID: 67650463092     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.707     Document Type: Article

References (28)

1. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci. 2001; 936: 11-30. (Pubitemid 32613890)
2. Collet JP, Lesty C, Montalescot G, et al. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem. 2003; 278: 21331-21335. (Pubitemid 36792527)
3. Undas A, Szuldrzynski K, Stepien E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: Effects of inflammation and oxidative stress. Atherosclerosis. 2007; 196: 551-558.
4. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006; 26: 2567-2573. (Pubitemid 44607482)
5. Undas A, Podolec P, Zawilska K, et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischemic stroke. Stroke. 2009; 40: 1499-1501.
6. Scott EM, Ariëns RAS, Grant PJ. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004; 24: 1558-1566.
7. Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009; 15: 467-478.
8. Undas A, Celinska-Lowenhoff M, Kaczor M, et al. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost. 2004; 91: 1065-1077. (Pubitemid 38821261)
9. Hart RG. What's new in stroke? The top 10 studies of 2006-2008. Part II. Pol Arch Med Wewn. 2008; 118: 747-755.
10. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005; 25: 287-294.
11. Ramcharan AS, van Stralen KJ, Snoep JD, et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost. 2009; 7: 514-520.
12. Sorensen HT, Horvath-Puho E, Sogaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost. 2009; 7: 521-528.
13. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006; 4: 1029-1036.
14. Mills JD, Ariëns RA, Mansfield MW, et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation. 2002; 106: 1938-1942. (Pubitemid 35176298)
15. von dem Borne PA, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995; 86: 3035-3042.
16. Lisman T, Leebeek FWG, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001; 121: 131-139. (Pubitemid 32591523)
17. Maison P, Mennen L, Sapinho D, et al. D.E.S.I.R. Study Group. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis. 2002; 160: 155-160.
18. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med. 2003; 139: 670-682. (Pubitemid 38124539)
19. Krysiak R, Okopien B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs. 2003; 63: 1821-1854. (Pubitemid 37083030)
20. Salonen EM, Vartio T, Hedman K, et al. Binding of fibronectin by the acute phase C-reactive protein. J Biol Chem. 1984; 259: 1496-1501. (Pubitemid 14104199)
21. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost. 1992; 68: 130-135.
22. Undas A, Plicner D, Stepien E, et al. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a), and homocysteine. J Thromb Haemost 2007; 5: 1988-1990. (Pubitemid 47288965)
23. Undas A, Brożek J, Jankowski M, et al. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol. 2006; 26: 1397-1404. (Pubitemid 44305388)
24. Undas A, Stepien E, Tracz W, et al. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost. 2006; 4: 973-975.
25. Sjoland JA, Sidelmann JJ, Brabrand M, et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost. 2007; 98: 339-345. (Pubitemid 47250237)
26. Dembowski E, Davidson MH. Should every patient with diabetes receive a statin? Pol Arch Med Wewn. 2008; 118: 398-401.
27. Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Medicinal Chem. 2008; 6: 161-180.
28. Undas A, Brummel K, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001; 103: 2248-2253. (Pubitemid 32433713)